BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Monday, July 14, 2025
See today's BioWorld Asia
See today's BioWorld
Home
» Invox Pharma to acquire F-star for $161M to build Sino Biopharm presence outside China
To read the full story,
subscribe
or
sign in
.
Invox Pharma to acquire F-star for $161M to build Sino Biopharm presence outside China
June 28, 2022
By
Tamra Sami
London-based Invox Pharma Ltd. has announced plans to acquire F-star Therapeutics Inc. for $161 million to build up the presence of its parent company, Sino Biopharm Ltd., outside of China.
BioWorld
BioWorld Asia
Deals and M&A
Cancer
China